Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02475447 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis
A Phase 2 study, sponsored by Tioga Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 249
- Enrollment target
NCT02475447 is a Phase 2 study that has completed, run by Tioga Pharmaceuticals. The registered enrollment target is 249 participants.
The verdict
NCT02475447, a Phase 2 study, has completed, sponsored by Tioga Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 249 participants
- Enrollment target
Study Summary
Kappa-opioid receptors mediate the sensation of itch in animals and humans. Asimadoline is an orally active, selective kappa-opioid receptor agonist and has demonstrated efficacy in several preclinical pruritus models. The purpose of this Phase 2 study is to evaluate the safety, tolerability and clinical efficacy of asimadoline in patients with pruritus associated with atopic dermatitis.
Interventions
- DRUG Placebo
- DRUG Asimadoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02475447
The ClinicalTrials.gov registry entry for NCT02475447 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tioga Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02475447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02475447 about?
NCT02475447 is a clinical study titled "Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis". Kappa-opioid receptors mediate the sensation of itch in animals and humans. Asimadoline is an orally active, selective kappa-opioid receptor agonist and has demonstrated efficacy in several preclinical pruritus models. The purpose of this Phase 2 study is to evaluate the safety, tolerability and cli...
What is the current status of trial NCT02475447?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 249 participants. The study started on 2015-07. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02475447?
The interventions under investigation include: Placebo (DRUG), Asimadoline (DRUG).
Who is sponsoring clinical trial NCT02475447?
This trial is sponsored by Tioga Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.